Last reviewed · How we verify

NCT05713760

Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

Completed Phase 2 Last updated 19 July 2024
What this trial tests

Phase 2 trial testing Tirbanibulin Ointment 1% in Superficial Basal Cell Carcinoma in 5 participants. Completed in 7 March 2024.

Timeline
17 April 2023
Primary endpoint
7 March 2024
7 March 2024

Quick facts

Lead sponsorAustin Institute for Clinical Research
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingnone
Primary purposetreatment
Enrollment5
Start date17 April 2023
Primary completion7 March 2024
Estimated completion7 March 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Austin Institute for Clinical Research

Who can join

18 and older, any sex, with Superficial Basal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.
    Liu Z, Zhang X, Ben T, Li M, et al · · 2025 · cited 12× · PMID 40045379 · DOI 10.1186/s40364-025-00745-7
  2. Synthesis and evaluation of tirbanibulin derivatives: a detailed exploration of the structure-activity relationship for anticancer activity.
    Park J, Kang M, Lim A, Cho KJ, et al · · 2023 · cited 2× · PMID 38077981 · DOI 10.1039/d3ra06790d

Verify or expand the search:

Other recruiting trials for Superficial Basal Cell Carcinoma

Currently open trials in the same condition.

Other Austin Institute for Clinical Research trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05713760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing